China's WuXi PharmaTech has launched an app to allow clients to order its chemistry services on the go, touting it as an industry first as the CRO works to claim more of the small-molecule services market.
Improprieties at a GVK Biosciences facility in India have led some European countries to pull medicines from shelves, and the resulting fallout is cutting into the CRO's profits.
A malfunctioning thermostat led to the deaths of 13 research primates at a Covance facility, according to authorities, and the CRO could be in line for federal punishment.
PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.
X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program.
German contract developer Evotec pocketed €8 million ($10 million) from its ongoing R&D collaborations with Bayer and Johnson & Johnson, capping a big year for the innovative company.
Contract researcher KCR is dialing up its presence in Ukraine, buying out a competitor's whole clinical portfolio and doubling down on a country it believes is ripe for R&D growth.
WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
Health Decisions, a week removed from the plane crash that claimed the life of its CEO, has recruited a CRO veteran from the University of North Carolina to step in as interim chief executive and oversee its transition.
BioClinica, fresh from its latest merger, has named a Pfizer executive as its next CEO.
North Carolina CRO Health Decisions is working its way back to normalcy after the death of its founder and CEO, processing a loss that "devastated" its staff, an executive said.
Covance got some bad advice when it agreed to a roughly $6 billion buyout from LabCorp, according to an investor lawsuit, which alleges that chief dealbroker Goldman Sachs had a conflict of interest all along.
Kidney dialysis magnate DaVita HealthCare Partners has merged its two research-minded subsidiaries to create an end-to-end CRO focused on renal trials.
Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.
Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.
Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.
WuXi PharmaTech is moving toward an IPO for one of its R&D and manufacturing subsidiaries, hoping to take advantage of a new market in its native China.